Chris Raymond
Stock Analyst at Raymond James
(2.97)
# 1,372
Out of 5,113 analysts
9
Total ratings
66.67%
Success rate
62.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $65.99 | +86.39% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $44.21 | +1.79% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $22.99 | +52.24% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $101.34 | +3.61% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $10.42 | +120.73% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $37.90 | -20.84% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $11.13 | +573.85% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $65.99
Upside: +86.39%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $44.21
Upside: +1.79%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $22.99
Upside: +52.24%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $101.34
Upside: +3.61%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $10.42
Upside: +120.73%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $37.90
Upside: -20.84%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $11.13
Upside: +573.85%